8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis | PLOS ONE
Salomon Anne - avis, photos, numéro de téléphone et adresse - Hôpitaux vétérinaires à Grand Est - Nicelocal.fr
![HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01158-3/MediaObjects/13045_2021_1158_Fig1_HTML.png)
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
![Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences](https://qima-lifesciences.com/wp-content/uploads/2019/09/mw_Oncostatin-M-2019.png)
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences
![Genome‐wide analysis of hybridization in wild boar populations reveals adaptive introgression from domestic pig - Mary - 2022 - Evolutionary Applications - Wiley Online Library Genome‐wide analysis of hybridization in wild boar populations reveals adaptive introgression from domestic pig - Mary - 2022 - Evolutionary Applications - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/88ba0f7d-c5c3-4dd0-8796-9dac17027171/eva.v15.7.cover.jpg)
Genome‐wide analysis of hybridization in wild boar populations reveals adaptive introgression from domestic pig - Mary - 2022 - Evolutionary Applications - Wiley Online Library
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8662740/bin/nihms-1731291-f0002.jpg)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8662740/bin/nihms-1731291-f0005.jpg)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine](https://www.science.org/cms/asset/aff01e29-3536-466a-9bbc-a839e7e344f4/aax2625-f1.gif)